Twelve-Month Efficacy of Intravitreal Bevacizumab Injection for Chronic, Atypical, or Recurrent Central Serous Chorioretinopathy

Chung, Yoo‐Sam; Kim, Jong Wan; Song, Jongtae; Park, Aram; Kim, Min Ho

doi:10.1097/iae.0000000000001917

Cited by 21 publications

(21 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, Spearman's rank correlation coefficient clearly indicated the presence of significant correlations among the angiogenic cytokines in the chronic CSC group, whereas the correlations among these cytokines in the acute CSC groups were significantly lower. Anti-VEGF therapy has been reported as an effective treatment for chronic CSC 44,45 and PNV. 27,46 The gradual increase of VEGF and PlGF along with disease progression may suggest that CNV arises as a consequence of angiogenic cytokine accumulation, triggered by aberrant interaction between dysregulated RPE and macrophages.…”

Section: Discussionmentioning

confidence: 99%

Association of Upregulated Angiogenic Cytokines With Choroidal Abnormalities in Chronic Central Serous Chorioretinopathy

Terao

Koizumi

Kojima

et al. 2018

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PURPOSE. To clarify the distinct molecular pathogenesis of central serous chorioretinopathy (CSC) and pachychoroid neovasculopathy (PNV). METHODS. Aqueous humor (AH) was collected from 18 acute CSC, 20 chronic CSC, and 20 PNV patients. Concentrations of 30 cytokines in the AH were analyzed using a multiplex bead immunoassay, and the cytokine profiles were compared among these three groups of patients. The areas of choroidal vascular hyperpermeability (CVH) and choroidal thickness (CT), including measurement of the vascular layers, were investigated to analyze the features of choroidal abnormality in acute CSC, chronic CSC, and PNV. Additionally, associations between cytokine profiles and choroidal abnormalities were analyzed. RESULTS. Proinflammatory cytokines, IL-6 and IL-8 were significantly upregulated in the chronic CSC group compared with the acute CSC or PNV groups. Angiogenic cytokines and VEGF-A were upregulated at levels that almost reached significance along with disease progression from acute to chronic CSC, whereas the upregulation was not significant from chronic CSC to PNV. In the chronic CSC group, strong positive correlations were confirmed between VEGF-A and placental growth factor (PlGF) (r ¼ 0.75, P < 0.001) and IL-6 and VEGF-A (r ¼ 0.74, P < 0.001), and angiogenesis-related cytokines were positively correlated with the typical choroidal abnormalities, areas of CVH, mean CT, and mean large choroidal vessel layer thickness. However, there was no association between these choroidal abnormality parameters and AH cytokines in the PNV group. CONCLUSIONS. The results suggest that choroidal abnormalities in chronic CSC may be associated with upregulated angiogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of Upregulated Angiogenic Cytokines With Choroidal Abnormalities in Chronic Central Serous Chorioretinopathy

Terao

Koizumi

Kojima

et al. 2018

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…In the retrospective study, Chung et al. evaluated the efficacy of IVB injection in the treatment of 77 eyes from 71 patients with chronic, atypical, or recurrent CSC 36 . They injected IVB in 6-week intervals until SRF absorption and then based on an as-needed protocol according to OCT findings.…”

Section: Discussionmentioning

confidence: 99%

Intravitreal bevacizumab administration for the treatment of chronic central serous chorioretinopathy

Alishiri

Jadidi

Mosavi

et al. 2019

Journal of Current Ophthalmology

View full text Add to dashboard Cite

PurposeTo evaluate the effects of intravitreal bevacizumab (IVB) injection on chronic central serous chorioretinopathy (CSC).MethodsIn this prospective interventional case series, a total of 22 eyes of 22 patients, diagnosed with unresolved CSC for three months or longer, received 1.25 mg IVB injection. Also, in case of failure to achieve success parameters, double dose IVB injections continued in order to reach the complete subretinal fluid (SRF) absorption. A complete ophthalmic assessment was carried out one day, one week, and one-month post-injection, and then a monthly visit was performed, and re-injection was done if needed. Visual acuity, subretinal space volume (SSV), central macular thickness (CMT), and contrast sensitivity were measured and compared among baseline values and final post-treatment values.ResultsThe mean best corrected visual acuity increased significantly from 0.70 ± 0.22 to 0.17 ± 0.15 logMAR (P <0.001), and the CMT showed a significant reduction from 557.36 ± 129.12 to 259.50 ± 116.73 μm (P <0.001 ). In addition, SSV decreased significantly from 10.53 ± 2.03 to 6.63 ± 1.80 (P = 0.001), and contrast sensitivity improved significantly from 13.8182 ± 2.64820 dB to 17.6818 ± 1.80967 dB (P <0.001).ConclusionIn this series, SRF absorption occurred and visual acuity improved after IVB injections, however, further comparative studies are needed to show the effect of IVB in chronic CSC.

show abstract

“…Indeed, retrospective evaluation of intravitreal bevacizumab treatment in patients with chronic and recurrent CSC (77 eyes of 71 patients) showed reduction in central retinal thickness and associated improved visual acuity. [ 38 ] However, a randomised controlled trial of 32 eyes of 34 patients comparing ranibizumab and half-fluence PDT in patients with chronic CSC suggested that PDT treatment was superior (in both resolution of subretinal fluid and improvement in visual acuity). [ 39 ]…”

Section: Treatment Strategies For Central Serous Chorioretinopathymentioning

confidence: 99%

“…[ 43 ] Furthermore, a recent retrospective study evaluating patients with chronic or recurrent CSC showed that intravitreal bevacizumab was useful in reduced in choroidal thickness and improving visual outcomes at 1 year. [ 38 ] These studies have promising results for anti-VEGF treatment in CSC, although it would be useful to also exclude concurrent CNV with OCTA.…”

Section: Treatment Strategies For Central Serous Chorioretinopathymentioning

confidence: 99%

Management of chronic central serous chorioretinopathy

Hanumunthadu

Tan

Singh

et al. 2018

Indian J Ophthalmol

View full text Add to dashboard Cite

New treatment modalities for the management of central serous chorioretinopathy (CSC) now exist. While acute CSC generally resolves without the requirement for intervention, chronic CSC has been associated with persistent disruption in visual function. Current treatment approaches include photodynamic therapy, oral aldosterone antagonism and subthreshold multifocal laser. There has also been further investigation into a number of new treatments including antivascular endothelial growth factor treatment. Further investigation using developing optical coherence tomography imaging is helping to determine biomarkers of CSC activity, potential indicators of treatment response and indications of chronicity of disease activity. Further comparative study is required to determine the effectiveness of different forms of treatment in a range of patients with varied demographics, aetiology and chronicity of disease.

show abstract

Twelve-Month Efficacy of Intravitreal Bevacizumab Injection for Chronic, Atypical, or Recurrent Central Serous Chorioretinopathy

Abstract: As-needed optical coherence tomography-based IVB was effective for reducing CRT in patients with chronic, atypical, or recurrent CSC, and for vision improvement in chronic and recurrent CSC over the 1-year follow-up period.

Cited by 21 publications

References 40 publications

Association of Upregulated Angiogenic Cytokines With Choroidal Abnormalities in Chronic Central Serous Chorioretinopathy

Association of Upregulated Angiogenic Cytokines With Choroidal Abnormalities in Chronic Central Serous Chorioretinopathy

Intravitreal bevacizumab administration for the treatment of chronic central serous chorioretinopathy

Management of chronic central serous chorioretinopathy

Contact Info

Product

Resources

About